Broker P.,University of Potsdam |
Lucke K.,GILUPI GmbH |
Perpeet M.,SAW Instruments |
Gronewold T.M.A.,SAW Instruments
Sensors and Actuators, B: Chemical | Year: 2012
A nanostructured chip surface was fabricated enabling binding via spaced antibodies specifically targeting surface proteins of cancer cells and detection of extremely low numbers of circulating tumor cells (CTC) without labeling using a sam ® 5 biosensor. The antibody surfaces mostly were generated by self assembly of antibodies to gold nanospots on the sensitive SiO 2-surface of a sam ® 5 chip. Compared with a complete gold surface, only 40% of the amount of antibodies was bound to the nanospot surface, but structured such that 15-fold higher sensitivity to vital cancer cells was achieved. Human cancer cell lines JEG-3 (lymphoblastic leukemia) and MOLT-17 (placental choriocarcinoma) from cell cultures were successfully detected. The sensor showed significant responses on less than 10 cells injected in a single run. The extreme increase in sensitivity and its simple regeneration emphasizes the usefulness of its introduction in biomedical applications. © 2012 Elsevier B.V. All rights reserved. Source
GILUPI GmbH | Date: 2011-03-15
The invention concerns a Biodetector with a functionalised surface for isolating molecules or cells from the human body. In order to improve a Biodetector of the type mentioned above such that the functionalised surface of the Biodetector or there upon enriched molecules or cells are exposed to a lower abrasion, and the biocompatibility of the Biodetector is improved, the Biodetector is designed to remove a fluid from the human body and absorb it into an inner space of the Biodetector, wherein the functionalised surface is oriented to the inner space of the Biodetector.
GILUPI GmbH | Date: 2010-06-17
The present invention refers to a detection device for the in vivo and/or in vitro enrichment of sample material, the detection device comprising a functional surface equipped with detection receptors. To further improve the enrichment of sample material by using a detection device of the aforementioned type, it is provided according to the invention that the functional surface has a three-dimensional structure with mutually facing functional sections which form spaces that can be filled with a sample liquid. Furthermore, the present invention provides for a use and for a method for the use of the detection device.
Svensson C.-M.,Leibniz Institute for Natural Product Research and Infection Biology |
Svensson C.-M.,Goethe University Frankfurt |
Krusekopf S.,GILUPI GmbH |
Lucke J.,Goethe University Frankfurt |
And 4 more authors.
Cytometry Part A | Year: 2014
Personalized medicine is a modern healthcare approach where information on each person's unique clinical constitution is exploited to realize early disease intervention based on more informed medical decisions. The application of diagnostic tools in combination with measurement evaluation that can be performed in a reliable and automated fashion plays a key role in this context. As the progression of various cancer diseases and the effectiveness of their treatments are related to a varying number of tumor cells that circulate in blood, the determination of their extremely low numbers by liquid biopsy is a decisive prognostic marker. To detect and enumerate circulating tumor cells (CTCs) in a reliable and automated fashion, we apply methods from machine learning using a naive Bayesian classifier (NBC) based on a probabilistic generative mixture model. Cells are collected with a functionalized medical wire and are stained for fluorescence microscopy so that their color signature can be used for classification through the construction of Red-Green-Blue (RGB) color histograms. Exploiting the information on the fluorescence signature of CTCs by the NBC does not only allow going beyond previous approaches but also provides a method of unsupervised learning that is required for unlabeled training data. A quantitative comparison with a state-of-the-art support vector machine, which requires labeled data, demonstrates the competitiveness of the NBC method. © 2014 International Society for Advancement of Cytometry. Source
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2013.3.3 | Award Amount: 5.30M | Year: 2014
Through further development, integration and validation of micro-nano-bio and biophotonics systems from previous projects CanDo will develop an instrument that will permit the identification and concentration determination of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy determination and cancer diagnosis/monitoring.A cellular link between the primary malignant tumor and the peripheral metastases, responsible for 90% of cancer-related deaths, has been established in the form of circulating tumor cells (CTCs) in peripheral blood. Furthermore the relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumor progression thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumor progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. Similarly problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often preventing access to market. There is therefore a clear need for a novel analytical platform capable of highly reproducible and reliable identification of CTC concentrations of interest in an easily accessible format.With all relevant industrial stakeholders and users onboard CanDo is uniquely capable of delivering such a platform. Its novel cell separation/SERS analysis technologies plus nucleic acid based molecular characterization will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and cancer diagnostics but due to modular technologies in others e.g. transport, security and safety and environment.